Ara
Toplam kayıt 76, listelenen: 71-76
Digoxin Exhibits Neuroprotective Properties in a Rat Model of Dementia
(Springer/Plenum Publishers, 2022)
Alzheimer's disease (AD) is by far the most common cause of cognitive impairment in older adults. Current treatments are entirely focused on the symptoms of AD. A complex etiology for AD has been proposed recently, in which ...
Demonstration of the protective effect of propofol in rat model of cisplatin-induced neuropathy
(Aepress Sro, 2023)
Cisplatin is commonly used in the treatment of lung, genitourinary, and gastrointestinal cancers. Peripheral neuropathy is the most important side effect, leading to a decrease in the dose of cisplatin or its complete ...
N-acetyl cysteine: A new look at its effect on PTZ-induced convulsions
(Elsevier, 2023)
Introduction/Aim: Epilepsy is widely investigated as a common neurological disease requiring pharmacologically effective agents. N-acetyl cysteine (NAC), has become a remarkable molecule with its role in both antioxidant ...
Prenatal Exposure to COVID-19 mRNA Vaccine BNT162b2 Induces Autism-Like Behaviors in Male Neonatal Rats: Insights into WNT and BDNF Signaling Perturbations
(Springer/Plenum Publishers, 2024)
The COVID-19 pandemic catalyzed the swift development and distribution of mRNA vaccines, including BNT162b2, to address the disease. Concerns have arisen about the potential neurodevelopmental implications of these vaccines, ...
Immunosuppressant Tacrolimus Treatment Delays Acute Seizure Occurrence, Reduces Elevated Oxidative Stress, and Reverses PGF2? Burst in the Brain of PTZ-Treated Rats
(Springer/Plenum Publishers, 2023)
It is still an urgent need to find alternative and effective therapies to combat epileptic seizures. Tacrolimus as a potent immunosuppressant and calcineurin inhibitor is emerging as promising drug to suppress seizures. ...
Effects of Diclofenac Sodium on Seizure Activity in Rats with Pentylenetetrazole-Induced Convulsions
(Springer/Plenum Publishers, 2023)
Epilepsy is a disease which affects between 1 and 2% of the population, and a large proportion of these people do not react to currently available anticonvulsant medications, indicating the need for further research into ...